![FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes](https://cardiovascularbusiness.com/sites/default/files/styles/top_stories/public/2022-05/screen_shot_2022-05-24_at_11.24.40_am.png.webp?itok=cecCZ20-)
FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes
Public Assessment Report Decentralised Procedure Anagrelide 0.5 mg hard capsules Anagrelide 1 mg hard capsules (Anagrelide hydro
![Teva Recalls One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Teva Recalls One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](https://media.americanpharmaceuticalreview.com/m/28/article/586636.jpg)
Teva Recalls One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Foglio illustrativo: Informazioni per il paziente Anagrelide Teva 0,5 mg capsule rigide anagrelide Medicinale equivalente Legga
![These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997 These highlights do not include all the information needed to use ANAGRELIDE CAPSULES safely and effectively. See full prescribing information for ANAGRELIDE CAPSULES. ANAGRELIDE capsules, for oral useInitial U.S. Approval: 1997](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=image-4.jpg&id=639733)